Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Blood

Volumn 112, Issue 10, 2008, Pages 3989-3994

  Kobe, Carsten ^a   Dietlein, Markus ^a   Franklin, Jeremy ^a   Markova, Jana ^b   Lohri, Andreas ^c   Amthauer, Holger ^d   Klutmann, Susanne ^e   Knapp, Wolfram H ^f   Zijlstra, Josee M ^g   Bockisch, Andreas ^h   Weckesser, Matthias ⁱ   Lorenz, Reinhard ^j   Schreckenberger, Mathias ^k   Bares, Roland ^l   Eich, Hans T ^a   Mueller, Rolf Peter ^a   Fuchs, Michael ^a   Borchmann, Peter ^a   Schicha, Harald ^a   Diehl, Volker ^a   Engert, Andreas ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^l UNIVERSITY OF TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICALS; RISK FACTORS; SURVIVAL RATE; VINCRISTINE;

EID: 57349106625     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-155820     Document Type: Article

References (24)

1. Diehl V, Mauch PM, Harris NL. Hodgkin's disease. In: DeVita VT, Hellmann S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2339-2387.
2. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3439.
4. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomized trials. Ann Oncol. 2006;17:1749-1760.
5. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348:2386-2395.
6. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease: International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998;16: 818-829.
7. Aleman MB, Raemaekers JM, Tirelli U, et al. Involved- field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348:2396-2406.
8. Eich HT, Gossmann A, Engert A, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma: analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys. 2007;69:1187-1192.
9. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001;12:29-37.
10. Spaepen K, Stroobants S, Dont P, et al. Can positron emission tomography with [(18F)]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272-278.
11. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18Ffluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood. 2001;98: 2930-2934.
12. Sieber M, Bredenfeld H, Josting A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednison regimen in advanced-stage Hodgkin lymphoma: results of a pilot study of the German Hodgkin's Lymphoma study group. J Clin Oncol. 2003;21:1734-1739.
13. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
15. Jox A, Zander T, Kornacker M, et al. Detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin's disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half year later. Ann Oncol. 1998;9:283-287.
16. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian- Danish study. J Clin Oncol. 2007;25:3746-3752.
17. Dann EJ, Bar-Shalom R, Tamir A, et al. Riskadapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood. 2007;109:905-909.
18. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TH. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy. Is biopsy of FDG-avid lesions still needed? Radiology. 2007;244:257-262.
19. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-1300.
20. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDGPET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160- 1168.
21. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
22. Kasamon YL, Wahl RL. FDG PET and riskadapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol. 2008;20:206-219.
23. Avigdor A, Bulvik S, Dann E, et al. Combined escBEACOPP- ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: an effective regimen and low positive predictive value of early FDG-PET/CT Scan. Blood. 2007;110:686a. Abstract 2319.
24. Gallamini A, Hutchings M, Avigdor A, Polliack A. Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma. 2008;49: 659-662.